Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Alzheimer’s disease patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download.
Use the Extrapolated Worldwide Coverage dashboard to do the following:
View 10-year forecasts of the diagnosed prevalent cases and diagnosed moderate to severe prevalent cases for all 171 countries, stratified by region and World Bank income status.
Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
Generate and export global heat maps of disease risk or patient population size.
The Extrapolated Worldwide Coverage dashboard is available as an Excel file in the “Downloads” section. It is available for purchase by clients who subscribe to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact DRG.support@clarivate.com.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.
